½ÃÀ庸°í¼­
»óǰÄÚµå
1421057

¼¼°èÀÇ ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀå Á¶»ç º¸°í¼­ : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2032³â)

Global Clinical Communication & Collaboration Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Value Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 236 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀåÀÇ ¼¼°è ¼ö¿ä´Â 2023³â 39¾ï 2,000¸¸ ´Þ·¯¿¡¼­ 2032³â¿¡´Â °ÅÀÇ 193¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, 2024³âºÎÅÍ 2032³â±îÁö 19.42%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷(CC&C)Àº ÀÇ·á Àü¹®°¡µéÀÌ ÀÓ»ó ÇöÀå¿¡¼­ Ä¿¹Â´ÏÄÉÀ̼Ç, Çù¾÷ ¹× ȯÀÚ Ä¡·á Á¶Á¤À» À§ÇØ »ç¿ëÇÏ´Â ÅëÇÕ ½Ã½ºÅÛ, ±â¼ú ¹× ÇÁ·Î¼¼½º¸¦ ¸»Çϸç, CC&CÀÇ ¸ñÀûÀº Ä¿¹Â´ÏÄÉÀÌ¼Ç È¿À²À» ³ôÀ̰í Ä¡·á Çù·ÂÀ» °³¼±ÇÏ¿© ±Ã±ØÀûÀ¸·Î ȯÀÚ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ ±â¿©ÇÏ´Â °ÍÀÔ´Ï´Ù. °³¼±Çϰí, ±Ã±ØÀûÀ¸·Î ȯÀÚ °á°ú °³¼±¿¡ ±â¿©ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀåÀº ÇコÄÉ¾î ºÐ¾ß¿¡¼­ È¿À²ÀûÀÎ Ä¿¹Â´ÏÄÉÀ̼ÇÀÇ Çʿ伺À» °­Á¶ÇÏ´Â ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ȯÀÚ Ä¡·áÀÇ Áú Çâ»ó¿¡ ÃÊÁ¡À» ¸ÂÃß°í, ÀüÀÚ ÀÇ·á ±â·Ï ¹× ¿ø°Ý ÀÇ·áÀÇ µµÀÔ°ú °°Àº ÀÇ·á ºÐ¾ßÀÇ µðÁöÅÐ Çõ½ÅÀÇ ±¤¹üÀ§ÇÑ Ãß¼¼¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ƯÈ÷ µ¥ÀÌÅÍ º¸¾È ¹× ÇÁ¶óÀ̹ö½Ã(HIPAA µî)¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ Áؼö ¿ä°ÇÀº ±ÔÁ¦ Áؼö¸¦ ¿ì¼±½ÃÇÏ´Â CC&C Ç÷§Æû¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ȯÀÚ »ç·ÊÀÇ º¹À⼺Àº ¿ø°Ý ÀÇ·á ¹× ¿ø°Ý Áø·á ¸ðµ¨ÀÇ ºÎ»ó°ú ÇÔ²² ÅëÇÕ Ä¿¹Â´ÏÄÉÀÌ¼Ç µµ±¸ÀÇ Çʿ伺À» °­Á¶Çϰí ÀÖÀ¸¸ç, COVID-19 ÆÒµ¥¹ÍÀÇ ¿µÇâÀ¸·Î ÇコÄÉ¾î ºÐ¾ß¿¡¼­ µðÁöÅÐ Ä¿¹Â´ÏÄÉÀÌ¼Ç ¼Ö·ç¼ÇÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¶ÇÇÑ ÀÇ·á Àü¹®°¡¿Í ȯÀÚ °£ÀÇ È¿°úÀûÀÎ Ä¿¹Â´ÏÄÉÀ̼ÇÀ» Áß½ÃÇϴ ȯÀÚ Á᫐ Áø·á ¸ðµ¨·Î ÀüȯÇÏ´Â Ãß¼¼¿Íµµ ¸Â¹°·Á ÀÖ½À´Ï´Ù. ÀÇ·á ±â°üÀÌ Áø·á Á¶Á¤, »óÈ£¿î¿ë¼º, ±âÁ¸ ÀÇ·á IT ÀÎÇÁ¶ó¿ÍÀÇ ¿øÈ°ÇÑ ÅëÇÕÀ» Áö¿øÇÏ´Â ¼Ö·ç¼ÇÀ» ã°í ÀÖ´Â °¡¿îµ¥, CC&C ½ÃÀåÀº ÁøÈ­ÇÏ´Â ¾÷°èÀÇ ¿ä±¸¿¡ ºÎÀÀÇÏ¿© Áö¼ÓÀûÀÎ ¼ºÀåÀ» ÀÌ·ê Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

Á¶»ç º¸°í¼­´Â Porter's Five Forces ¸ðµ¨, ½ÃÀå ¸Å·Âµµ ºÐ¼®, ¹ë·ùüÀÎ ºÐ¼®À» ´Ù·ç°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µµ±¸´Â ¾÷°è ±¸Á¶¸¦ ¸íÈ®ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¼¼°è ¼öÁØ¿¡¼­ °æÀïÀÇ ¸Å·ÂÀ» Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¶ÇÇÑ ÀÌ·¯ÇÑ µµ±¸´Â ¼¼°è ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀåÀÇ °¢ ºÎ¹®À» Æ÷°ýÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ »ê¾÷ÀÇ ¼ºÀå°ú µ¿ÇâÀº ÀÌ Á¶»ç¿¡ ´ëÇÑ ÀüüÀûÀÎ Á¢±Ù ¹æ½ÄÀ» Á¦°øÇÕ´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀå º¸°í¼­ÀÇ ÀÌ ¼½¼Ç¿¡¼­´Â ±¹°¡ ¹× Áö¿ªº° ºÎ¹®¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·«°¡µéÀÌ °¢ Á¦Ç° ¶Ç´Â ¼­ºñ½ºÀÇ Å¸°ÙÃþÀ» ½Äº°Çϰí ÇâÈÄ ±âȸ¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù.

Àü°³º°

  • È£½ºÆ®Çü
  • ¿ÂÇÁ·¹¹Ì½º

±¸¼º¿ä¼Òº°

  • ¼Ö·ç¼Ç
  • ¼­ºñ½º

ÃÖÁ¾ ¿ëµµº°

  • º´¿ø
  • ÀÓ»ó°Ë»ç½Ç
  • ÀÇ»ç
  • ±âŸ

Áö¿ª ºÐ¼®

ÀÌ ¼½¼Ç¿¡¼­´Â ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀåÀÇ ÇöÀç ¹× ¹Ì·¡ ¼ö¿ä¸¦ °­Á¶ÇÏ´Â Áö¿ª Àü¸ÁÀ» ´Ù·ì´Ï´Ù. ¶ÇÇÑ, ¸ðµç ÁÖ¿ä Áö¿ªÀÇ °³º° ¾ÖÇø®ÄÉÀÌ¼Ç ºÎ¹®ÀÇ ¼ö¿ä, ÃßÁ¤ ¹× ¿¹Ãø¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ¿ä±¸ »çÇ×ÀÌ ÀÖ´Â °æ¿ì ´ç»ç¿¡ ¹®ÀÇÇϽʽÿÀ. ÀúÈñ Á¶»çÆÀÀº °í°´ÀÇ ¿ä±¸¿¡ µû¶ó ¸ÂÃãÇü º¸°í¼­¸¦ Á¦°ø ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ½ÃÀå ÇÏÀ̶óÀÌÆ®
  • ¼¼°è ½ÃÀå ÇöȲ

Á¦3Àå ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ - »ê¾÷ ºÐ¼®

  • ¼­·Ð : ½ÃÀå ¿ªÇÐ
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • ¾÷°è µ¿Çâ
  • Porter's Five Forces ºÐ¼®
  • ½ÃÀå ¸Å·Âµµ ºÐ¼®

Á¦4Àå ¹ë·ùüÀÎ ºÐ¼®

  • ¹ë·ùüÀÎ ºÐ¼®
  • ¿øÀç·á ºÐ¼®
    • ¿øÀç·á ¸®½ºÆ®
    • ¿øÀç·á Á¦Á¶¾÷ü ¸®½ºÆ®
    • ÁÖ¿ä ¿øÀç·á °¡°Ý µ¿Çâ
  • ÀáÀçÀû ¹ÙÀÌ¾î ¸®½ºÆ®
  • ¸¶ÄÉÆÃ Ã¤³Î
    • Á÷Á¢ ¸¶ÄÉÆÃ
    • °£Á¢ ¸¶ÄÉÆÃ
    • ¸¶ÄÉÆÃ Ã¤³Î ¹ßÀü µ¿Çâ

Á¦5Àå ¼¼°èÀÇ ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀå ºÐ¼® : Àü°³º°

  • Àü°³º° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • Àü°³º° ºÐ¼®
  • È£½ºÆ®Çü
  • ¿ÂÇÁ·¹¹Ì½º

Á¦6Àå ¼¼°èÀÇ ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀå ºÐ¼® : ÄÄÆ÷³ÍÆ®º°

  • ÄÄÆ÷³ÍÆ®º° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÄÄÆ÷³ÍÆ®º° ºÐ¼®
  • ¼Ö·ç¼Ç
  • ¼­ºñ½º

Á¦7Àå ¼¼°èÀÇ ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀå ºÐ¼® : ÃÖÁ¾ ¿ëµµº°

  • ÃÖÁ¾ ¿ëµµº° °³¿ä
  • ½ÇÀû µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅÍ
  • ÃÖÁ¾ ¿ëµµº° ºÐ¼®
  • º´¿ø
  • ÀÓ»ó °Ë»ç½Ç
  • ÀÇ»ç
  • ±âŸ

Á¦8Àå ¼¼°èÀÇ ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀå ºÐ¼® : Áö¿ªº°

  • Áö¿ªº° Àü¸Á
  • ¼­·Ð
  • ºÏ¹Ì ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ºÏ¹Ì : ºÎ¹®º°
    • ºÏ¹Ì : ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´ ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • À¯·´ : ºÎ¹®º°
    • À¯·´ : ±¹°¡º°
    • ¿µ±¹
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ºÎ¹®º°
    • ¾Æ½Ã¾ÆÅÂÆò¾ç : ±¹°¡º°
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • È£ÁÖ
    • µ¿³²¾Æ½Ã¾Æ
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • ¶óƾ¾Æ¸Þ¸®Ä« : ºÎ¹®º°
    • ¶óƾ¾Æ¸Þ¸®Ä« : ±¹°¡º°
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • Æä·ç
    • Ä¥·¹
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ¸ÅÃ⠺м®
    • °³¿ä, ½ÇÀû°ú ¿¹Ãø
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ºÎ¹®º°
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« : ±¹°¡º°
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • À̽º¶ó¿¤
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ±â¾÷ °æÀï »óȲ

  • ÀÓ»ó Ä¿¹Â´ÏÄÉÀÌ¼Ç ¹× Çù¾÷ ½ÃÀå °æÀï
  • ÆÄÆ®³Ê½Ê/Çù¾÷/ÇÕÀÇ
  • ÀμöÇÕº´
  • ½ÅÁ¦Ç° ¹ß¸Å
  • ±âŸ °³¹ß

Á¦10Àå ±â¾÷ °³¿ä

  • ±â¾÷ Á¡À¯À² ºÐ¼®
  • ½ÃÀå ÁýÁßµµ
  • TNS Inc.(AGNITY Inc.)
  • Avaya LLC
  • Oracle
  • Cisco Systems Inc.
  • Halo Health Systems
  • Hillrom & Welch Allyn(Baxter International)
  • Intel Corporation
  • Microsoft
  • NEC Corporation
  • Spok Holdings Inc.
  • Vocera Communications
  • Plantronics Inc.
ksm 24.02.16

The global demand for Clinical Communication & Collaboration Market is presumed to reach the market size of nearly USD 19.35 BN by 2032 from USD 3.92 BN in 2023 with a CAGR of 19.42% under the study period 2024 - 2032.

Clinical communication and collaboration (CC&C) refers to the integrated systems, technologies, and processes that healthcare professionals use to communicate, collaborate, and coordinate patient care within a clinical setting. The goal of CC&C is to enhance communication efficiency, improve care coordination, and ultimately contribute to better patient outcomes.

MARKET DYNAMICS

The Clinical communication and collaboration market is propelled by factors emphasizing the imperative for efficient communication within healthcare. With a focus on enhancing patient care quality, the market responds to the broader trend of digital transformation in healthcare, including the adoption of electronic health records and telehealth. Stringent regulatory compliance requirements, especially regarding data security and privacy (such as HIPAA), drive the demand for CC&C platforms that prioritize regulatory adherence. The increasing complexity of patient cases, coupled with the rise of telehealth and remote care models, accentuates the need for integrated communication tools. The impact of the COVID-19 pandemic has accelerated the adoption of digital communication solutions in healthcare. The market also aligns with the shift towards patient-centric care models, emphasizing effective communication between healthcare professionals and patients. As healthcare organizations seek solutions that support care coordination, interoperability, and seamless integration with existing health IT infrastructure, the CC&C market is poised for sustained growth in response to evolving industry needs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of clinical communication & collaboration. The growth and trends of clinical communication & collaboration industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the clinical communication & collaboration market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Deployment

  • Hosted
  • On-Premise

By Component

  • Solution
  • Services

By End-Use

  • Hospitals
  • Clinical Labs
  • Physicians
  • Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Clinical Communication & Collaboration market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Clinical Communication & Collaboration market include TNS Inc. (AGNITY Inc.), Avaya LLC, Oracle, Cisco Systems Inc., Halo Health Systems, Hillrom & Welch Allyn (Baxter International), Intel Corporation, Microsoft, NEC Corporation, Spok Holdings Inc., Vocera Communications, Plantronics Inc.. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

  • 1.1. Report Description
    • 1.1.1. Objective
    • 1.1.2. Target Audience
    • 1.1.3. Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3 . CLINICAL COMMUNICATION & COLLABORATION - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Deployment
    • 3.7.2 Market Attractiveness Analysis By Component
    • 3.7.3 Market Attractiveness Analysis By End-use
    • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1. List of Raw Materials
    • 4.2.2. Raw Material Manufactures List
    • 4.2.3. Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1. Direct Marketing
    • 4.4.2. Indirect Marketing
    • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL CLINICAL COMMUNICATION & COLLABORATION MARKET ANALYSIS BY DEPLOYMENT

  • 5.1 Overview by Deployment
  • 5.2 Historical and Forecast Data
  • 5.3 Analysis by Deployment
  • 5.4 Hosted Historic and Forecast Sales by Regions
  • 5.5 On-premise Historic and Forecast Sales by Regions

6 . GLOBAL CLINICAL COMMUNICATION & COLLABORATION MARKET ANALYSIS BY COMPONENT

  • 6.1 Overview by Component
  • 6.2 Historical and Forecast Data
  • 6.3 Analysis by Component
  • 6.4 Solution Historic and Forecast Sales by Regions
  • 6.5 Services Historic and Forecast Sales by Regions

7 . GLOBAL CLINICAL COMMUNICATION & COLLABORATION MARKET ANALYSIS BY END-USE

  • 7.1 Overview by End-use
  • 7.2 Historical and Forecast Data
  • 7.3 Analysis by End-use
  • 7.4 Hospitals Historic and Forecast Sales by Regions
  • 7.5 Clinical Labs Historic and Forecast Sales by Regions
  • 7.6 Physicians Historic and Forecast Sales by Regions
  • 7.7 Others Historic and Forecast Sales by Regions

8 . GLOBAL CLINICAL COMMUNICATION & COLLABORATION MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2. North America By Segment Sales Analysis
    • 8.3.3. North America By Country Sales Analysis
    • 8.3.4. United State Sales Analysis
    • 8.3.5. Canada Sales Analysis
    • 8.3.6. Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2. Europe by Segment Sales Analysis
    • 8.4.3. Europe by Country Sales Analysis
    • 8.4.4. United Kingdom Sales Analysis
    • 8.4.5. France Sales Analysis
    • 8.4.6. Germany Sales Analysis
    • 8.4.7. Italy Sales Analysis
    • 8.4.8. Russia Sales Analysis
    • 8.4.9. Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2. Asia Pacific by Segment Sales Analysis
    • 8.5.3. Asia Pacific by Country Sales Analysis
    • 8.5.4. China Sales Analysis
    • 8.5.5. India Sales Analysis
    • 8.5.6. Japan Sales Analysis
    • 8.5.7. South Korea Sales Analysis
    • 8.5.8. Australia Sales Analysis
    • 8.5.9. South East Asia Sales Analysis
    • 8.5.10. Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2. Latin America by Segment Sales Analysis
    • 8.6.3. Latin America by Country Sales Analysis
    • 8.6.4. Brazil Sales Analysis
    • 8.6.5. Argentina Sales Analysis
    • 8.6.6. Peru Sales Analysis
    • 8.6.7. Chile Sales Analysis
    • 8.6.8. Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2. Middle East & Africa by Segment Sales Analysis
    • 8.7.3. Middle East & Africa by Country Sales Analysis
    • 8.7.4. Saudi Arabia Sales Analysis
    • 8.7.5. UAE Sales Analysis
    • 8.7.6. Israel Sales Analysis
    • 8.7.7. South Africa Sales Analysis
    • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE CLINICAL COMMUNICATION & COLLABORATION COMPANIES

  • 9.1. Clinical Communication & Collaboration Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10 . COMPANY PROFILES OF CLINICAL COMMUNICATION & COLLABORATION INDUSTRY

  • 10.1. Company Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. TNS Inc. (AGNITY Inc.)
    • 10.3.1. Company Overview
    • 10.3.2. Company Revenue
    • 10.3.3. Products
    • 10.3.4. Recent Developments
  • 10.4. Avaya LLC
    • 10.4.1. Company Overview
    • 10.4.2. Company Revenue
    • 10.4.3. Products
    • 10.4.4. Recent Developments
  • 10.5. Oracle
    • 10.5.1. Company Overview
    • 10.5.2. Company Revenue
    • 10.5.3. Products
    • 10.5.4. Recent Developments
  • 10.6. Cisco Systems Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Company Revenue
    • 10.6.3. Products
    • 10.6.4. Recent Developments
  • 10.7. Halo Health Systems
    • 10.7.1. Company Overview
    • 10.7.2. Company Revenue
    • 10.7.3. Products
    • 10.7.4. Recent Developments
  • 10.8. Hillrom & Welch Allyn (Baxter International)
    • 10.8.1. Company Overview
    • 10.8.2. Company Revenue
    • 10.8.3. Products
    • 10.8.4. Recent Developments
  • 10.9. Intel Corporation
    • 10.9.1. Company Overview
    • 10.9.2. Company Revenue
    • 10.9.3. Products
    • 10.9.4. Recent Developments
  • 10.10. Microsoft
    • 10.10.1. Company Overview
    • 10.10.2. Company Revenue
    • 10.10.3. Products
    • 10.10.4. Recent Developments
  • 10.11. NEC Corporation
    • 10.11.1. Company Overview
    • 10.11.2. Company Revenue
    • 10.11.3. Products
    • 10.11.4. Recent Developments
  • 10.12. Spok Holdings Inc.
    • 10.12.1. Company Overview
    • 10.12.2. Company Revenue
    • 10.12.3. Products
    • 10.12.4. Recent Developments
  • 10.13. Vocera Communications
    • 10.13.1. Company Overview
    • 10.13.2. Company Revenue
    • 10.13.3. Products
    • 10.13.4. Recent Developments
  • 10.14. Plantronics Inc.
    • 10.14.1. Company Overview
    • 10.14.2. Company Revenue
    • 10.14.3. Products
    • 10.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦